Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

Fig. 5

Serum drug concentration–time profile for biosimilar, week 26 switch, and week 52 switch treatment groups A overall, B in ADA-positive patients, and C in ADA-negative patients. Summary statistics were calculated by setting concentration values below LLOQ to 0 (LLOQ = 250 ng/mL). Box plot provides median and 25%/75% quartiles with whiskers to the last point within 1.5 × the interquartile range. Unplanned readings were excluded from the presentation. Stars, circles, and squares represent median values. TP3 included data from week 56, week 66, EOT/ET, and follow-up visits. Data from week 52 represented samples obtained in TP2 prior to dosing and are included here for visualization purposes. ADA, anti-drug antibody; EOT, end of treatment; ET, early termination; LLOQ, lower limit of quantification; PK, pharmacokinetic; TP2, treatment period 2; TP3, treatment period 3

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us